AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17137743 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality graphs (15 years of data)
Number of subjects: 1461
Study 17137743 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality graphs (5 years of data)
Number of subjects: 1461
Study 17137743 — intervention group
Group type: COMPARATOR
Intervention: Survival graphs (15 years of data)
Number of subjects: 1461
Study 17137743 — intervention group
Group type: COMPARATOR
Intervention: Survival graphs (5 years of data)
Number of subjects: 1461
Study 15137922 — intervention group
Group type: EXPERIMENTAL
Intervention: 3R,3'R-zeaxanthin dipalmitate (5 mg)
Number of subjects: 12
Study 15137922 — intervention group
Group type: COMPARATOR
Intervention: non-esterified 3R,3'R-zeaxanthin (5 mg)
Number of subjects: 12
Study 15137922 — intervention group
Group type: EXPERIMENTAL
Intervention: 3R,3'R-zeaxanthin dipalmitate
Number of subjects: 12
Study 15137922 — intervention group
Group type: COMPARATOR
Intervention: non-esterified 3R,3'R-zeaxanthin
Number of subjects: 12
Study 11133608 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane with routine antiemetic prophylaxis
Number of subjects: 0
Study 9609607 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 400 microg bid
Number of subjects: 101
Study 9609607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 8093139 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg fluvastatin
Number of subjects: 224
Study 8093139 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fluvastatin
Number of subjects: 224
Study 8093139 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg fluvastatin plus 8 g cholestyramine
Number of subjects: 224
Study 8093139 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg fluvastatin plus 8 g cholestyramine
Number of subjects: 224
Study 8093139 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g cholestyramine in combination groups
Number of subjects: 224
Study 2804777 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy
Number of subjects: 56
Study 2804777 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemorrhoidectomy
Number of subjects: 56
Study 2804777 — intervention group
Group type: COMPARATOR
Intervention: Normal control
Number of subjects: 56
Study 31879317 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured chart review methodology by primary reviewers
Number of subjects: 327
Study 31879317 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured chart review methodology by secondary reviewers
Number of subjects: 327
Study 31879317 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplicate reviews
Number of subjects: 327
Study 31879317 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathophysiological categories
Number of subjects: 327
Study 31879317 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic categories
Number of subjects: 327
Study 27678010 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern radiotherapy techniques and field designs as part of the quality assurance program (QAP) developed by the expert panel.
Number of subjects: 11
Study 27678010 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance program (QAP) for modern radiotherapy (RT).
Number of subjects: 11
Study 25975733 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic bladder advice for 1 month followed by alarm therapy (group A)
Number of subjects: 40
Study 25975733 — intervention group
Group type: COMPARATOR
Intervention: Alarm therapy only (group B)
Number of subjects: 40
Study 23139373 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 10 mg weekly
Number of subjects: 1189
Study 23139373 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg weekly
Number of subjects: 1189
Study 23139373 — intervention group
Group type: COMPARATOR
Intervention: Exenatide 10 µg twice daily
Number of subjects: 1189
Study 20730547 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (average 12 lb, modal 19 lb)
Number of subjects: 0
Study 20730547 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (10% decrease in baseline weight)
Number of subjects: 0
Study 20730547 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study 19130937 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-standardized grass allergen tablet (Grazax)
Number of subjects: 253
Study 19130937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 16469980 — intervention group
Group type: EXPERIMENTAL
Intervention: Butter high in vaccenic acid (3.6 g vaccenic acid/d)
Number of subjects: 42
Study 16469980 — intervention group
Group type: COMPARATOR
Intervention: Control butter with low content of vaccenic acid
Number of subjects: 42
Study 15909709 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine exteriorization during caesarean section
Number of subjects: 136
Study 12792580 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 60
Study 12792580 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 60
Study 9928690 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of GP physicians in the ED
Number of subjects: 4694
Study 7759830 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin 4 g intravenously (group P)
Number of subjects: 379
Study 7759830 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin 4 g with sulbactam 2 g intravenously (group SP)
Number of subjects: 379
Study 7759830 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (P and SP)
Number of subjects: 379
Study 2216936 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 2216936 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 20
Study 2216936 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 80579 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 0
Study 80579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 80579 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (as second drug)
Number of subjects: 0
Study 31805386 — intervention group
Group type: EXPERIMENTAL
Intervention: Coil-type anchor
Number of subjects: 40
Study 31805386 — intervention group
Group type: COMPARATOR
Intervention: Screw-type anchor
Number of subjects: 40
Study 31805386 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study 31129442 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≥1 comorbidity (LVAD recipients)
Number of subjects: 239
Study 31129442 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pulmonary hypertension
Number of subjects: 239
Study 31129442 — intervention group
Group type: COMPARATOR
Intervention: Patients without pulmonary hypertension
Number of subjects: 239
Study 31129442 — intervention group
Group type: COMPARATOR
Intervention: Patients with chronic renal disease or high body mass index
Number of subjects: 239
Study 28185713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pitavastatin (4 mg/d)
Number of subjects: 60
Study 28185713 — intervention group
Group type: COMPARATOR
Intervention: Low-dose pitavastatin (2 mg/d)
Number of subjects: 60
Study 24842590 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces Intervention
Number of subjects: 71
Study 24842590 — intervention group
Group type: COMPARATOR
Intervention: Stories Intervention
Number of subjects: 71
Study 24842590 — intervention group
Group type: COMPARATOR
Intervention: Control Intervention
Number of subjects: 71
Study 23093223 — intervention group
Group type: EXPERIMENTAL
Intervention: D-serine (30 mg/kg) + CRT (5 h/week)
Number of subjects: 104
Study 23093223 — intervention group
Group type: EXPERIMENTAL
Intervention: D-serine + control CRT
Number of subjects: 104
Study 23093223 — intervention group
Group type: COMPARATOR
Intervention: CRT + placebo D-serine
Number of subjects: 104
Study 23093223 — intervention group
Group type: COMPARATOR
Intervention: placebo + control CRT
Number of subjects: 104
Study 22118312 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cromolyn sodium 2% ophthalmic solution without 0.01% benzalkonium chloride (BAK)
Number of subjects: 33
Study 22118312 — intervention group
Group type: COMPARATOR
Intervention: Topical cromolyn sodium 2% ophthalmic solution with 0.01% benzalkonium chloride (BAK)
Number of subjects: 33
Study 19189907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse discharge advocate intervention with follow-up appointments, medication reconciliation, and patient education
Number of subjects: 749
Study 19189907 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 749
Study 19189907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse discharge advocate intervention
Number of subjects: 749
Study 16917166 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 performed exercises which all incorporated volitional, planned head rotations.
Number of subjects: 80
Study 16917166 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 performed exercises that involved translating the body and incorporated volitional, planned head motion.
Number of subjects: 80
Study 16917166 — intervention group
Group type: COMPARATOR
Intervention: Group 1 viewed a video (control group).
Number of subjects: 80
Study 16917166 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 performed exercise that involved translating the entire body through space, but without separate, volitional head movement.
Number of subjects: 80
Study 14676595 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula supplemented with nucleotides (group F-NT)
Number of subjects: 150
Study 14676595 — intervention group
Group type: COMPARATOR
Intervention: Standard milk formula without nucleotides (group F)
Number of subjects: 150
Study 10674503 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA fentanyl
Number of subjects: 23
Study 10674503 — intervention group
Group type: COMPARATOR
Intervention: PCA alfentanil
Number of subjects: 23
Study 9324189 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 47
Study 9324189 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 47
Study 8404943 — intervention group
Group type: EXPERIMENTAL
Intervention: Taprostene (6.25, 12.5, or 25.0 ng.kg‐1 x min‐1) infused for 48 hours followed by a 24-hour tapering period.
Number of subjects: 80
Study 8404943 — intervention group
Group type: COMPARATOR
Intervention: Placebo infused for 48 hours followed by a 24-hour tapering period.
Number of subjects: 80
Study 8404943 — intervention group
Group type: EXPERIMENTAL
Intervention: Taprostene (up to 25 ng.kg‐1 x min‐1)
Number of subjects: 80
Study 3811811 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 30
Study 3811811 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 30
Study 31099402 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks + topical corticosteroids (TCS)
Number of subjects: 163
Study 31099402 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine + topical corticosteroids (TCS)
Number of subjects: 163
Study 28481157 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk information followed by gain-framed messages
Number of subjects: 237
Study 28481157 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk information followed by loss-framed messages
Number of subjects: 237
Study 28481157 — intervention group
Group type: COMPARATOR
Intervention: No risk information followed by gain-framed messages
Number of subjects: 237
Study 28481157 — intervention group
Group type: COMPARATOR
Intervention: No risk information followed by loss-framed messages
Number of subjects: 237
Study 25452300 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher systolic BP target (130-149 mm Hg)
Number of subjects: 3020
Study 25452300 — intervention group
Group type: COMPARATOR
Intervention: Lower systolic BP target (<130 mm Hg)
Number of subjects: 3020
Study 24097422 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 549
Study 24097422 — intervention group
Group type: COMPARATOR
Intervention: RV‐to‐pulmonary artery shunt
Number of subjects: 549
Study 24097422 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Norwood to pre-stage II
Number of subjects: 549
Study 24097422 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-stage II to 14 months
Number of subjects: 549
Study 21565530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg at the induction of anesthesia and at the initiation of CPB)
Number of subjects: 117
Study 21565530 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 117
Study 19782621 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronectomy
Number of subjects: 231
Study 19782621 — intervention group
Group type: COMPARATOR
Intervention: Total excision (Control)
Number of subjects: 231
Study 16826092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented stem fixation
Number of subjects: 24
Study 16826092 — intervention group
Group type: COMPARATOR
Intervention: Press-fit stem fixation
Number of subjects: 24
Study 16826092 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 14656250 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg vitamin B12
Number of subjects: 28
Study 14656250 — intervention group
Group type: COMPARATOR
Intervention: 1 mL saline placebo
Number of subjects: 28
Study 11429358 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg IV nalbuphine (n = 91)
Number of subjects: 181
Study 11429358 — intervention group
Group type: COMPARATOR
Intervention: 20 mg IV propofol (n = 90)
Number of subjects: 181
Study 9744436 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 45
Study 9744436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 7998585 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg orally daily (Group 1)
Number of subjects: 38
Study 7998585 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg every other day (Group 2)
Number of subjects: 38
Study 7998585 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg at the end of each dialysis session (Group 3)
Number of subjects: 38
Study 7998585 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg daily (Group 1)
Number of subjects: 38
Study 3377142 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled dipyridamole
Number of subjects: 13
Study 3377142 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 13
Study 31205187 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐02545920 5 mg
Number of subjects: 240
Study 31205187 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐02545920 15 mg
Number of subjects: 240
Study 31205187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 28593920 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 46
Study 28593920 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (SRL)
Number of subjects: 46
Study 26649542 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory training (AT) group (hearing aids + 3 week remotely delivered, Internet‐based auditory training program)
Number of subjects: 29
Study 26649542 — intervention group
Group type: COMPARATOR
Intervention: Control group (hearing aids alone)
Number of subjects: 29
Study 26649542 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory training (AT) group
Number of subjects: 29
Study 26649542 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 23752717 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Procedure (KP)
Number of subjects: 30
Study 23752717 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of Result (KR)
Number of subjects: 30
Study 23752717 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 30
Study 21993041 — intervention group
Group type: EXPERIMENTAL
Intervention: DMOI bat training (n = 9)
Number of subjects: 17
Study 19748406 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy (SMT)
Number of subjects: 30
Study 19748406 — intervention group
Group type: COMPARATOR
Intervention: Detuned ultrasound (placebo)
Number of subjects: 30
Study 16485227 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light filtering IOL (SN60AT, Alcon)
Number of subjects: 14
Study 16485227 — intervention group
Group type: COMPARATOR
Intervention: Conventional single‐piece IOL (SA60AT, Alcon)
Number of subjects: 14
Study 15483411 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin administration
Number of subjects: 3782
Study 15483411 — intervention group
Group type: COMPARATOR
Intervention: No albumin (control group)
Number of subjects: 3782
Study 15483411 — intervention group
Group type: COMPARATOR
Intervention: Low-dose albumin (control group)
Number of subjects: 3782
Study 15483411 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose albumin (control group)
Number of subjects: 3782
Study 10376237 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 25
Study 10376237 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 25
Study 10376237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 9081352 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI) at a dose of 33 Gy/11 fractions (45 patients) and 25 Gy/11 fractions (112 patients)
Number of subjects: 257
Study 9081352 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 257
Study 9081352 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with the best prognosis receiving PCI
Number of subjects: 257
Study 9081352 — intervention group
Group type: COMPARATOR
Intervention: Patients with the best prognosis not receiving PCI
Number of subjects: 257
Study 9081352 — intervention group
Group type: COMPARATOR
Intervention: Delayed late chest irradiation (LCI)
Number of subjects: 257
Study 1670734 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin taken at least once during the week before the first symptom
Number of subjects: 875
Study 1670734 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 875
Study 1670734 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 875
Study 1670734 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 875
Study 1670734 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 875
Study 1670734 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol, propyphenazone, and dipyrone
Number of subjects: 875
Study 6339708 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose amoxicillin therapy
Number of subjects: 49
Study 6339708 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (10-day course of amoxicillin)
Number of subjects: 49
Study 6339708 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-coated bacteria assay
Number of subjects: 49
Study 31864884 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on pharmacists' attitudes and current practice regarding their role in preconception, pregnancy, and lactation counseling.
Number of subjects: 63
Study 31864884 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on barriers to counseling during preconception, pregnancy, and lactation.
Number of subjects: 63
Study 31864884 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge test administered to pharmacists.
Number of subjects: 63
Study 31864884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mystery shopping scenarios including requests for pregnancy tests and OTC products for pregnancy-related nausea.
Number of subjects: 63
Study 29742744 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Myofascial Release (SMR)
Number of subjects: 49
Study 29742744 — intervention group
Group type: COMPARATOR
Intervention: Instrument-Assisted Soft-Tissue Mobilization (IASTM)
Number of subjects: 49
Study 31462477 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-week PEERS group
Number of subjects: 40
Study 31462477 — intervention group
Group type: COMPARATOR
Intervention: Waitlist care as usual group
Number of subjects: 40
Study 28426350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance 25 mg/d for 21 days of every 28-day cycle for 24 months
Number of subjects: 650
Study 28426350 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 650
Study 28426350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance
Number of subjects: 650
Study 28426350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 650
Study 25488331 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 10
Study 25488331 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 10
Study 23384237 — intervention group
Group type: EXPERIMENTAL
Intervention: Online health behavior intervention (U@Uni)
Number of subjects: 0
Study 23384237 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 21701174 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate + Levodopa (MPH + LD)
Number of subjects: 0
Study 21701174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18046048 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg oral testosterone enanthate (TE) twice daily plus 0.5 mg dutasteride daily
Number of subjects: 20
Study 18046048 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg oral testosterone enanthate (TE) once daily plus 0.5 mg dutasteride daily
Number of subjects: 20
Study 17057417 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 150
Study 17057417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 150
Study 17057417 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 150
Study 17057417 — intervention group
Group type: COMPARATOR
Intervention: Control group (all three LMWHs)
Number of subjects: 150
Study 15271105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination dorzolamide-timolol (Cosopt)
Number of subjects: 131